Reportlinker Adds World Growth Factors (Blood and Tissue) Market Report

NEW YORK--(Business Wire)--
Reportlinker.com announces that a new market research report is available in its
catalogue.

World Growth Factors (Blood And Tissue) Market

http://www.reportlinker.com/p098265/World-Growth-Factors-(Blood-And-Tissue)-Market.html

This report analyzes the worldwide markets for Growth Factors (Blood And Tissue)
in Millions of US$. The major product segments analyzed are Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), and
Tissue Growth Factors. The report provides separate comprehensive analytics for
the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each
region for the period of 2000 through 2015. The report profiles 90 companies
including many key and niche players worldwide such as Amgen, Inc., BioMimetic
Therapeutics, Inc., Biopharm GmbH, Bolder Biotechnology, Inc., Alseres
Pharmaceuticals, Inc., Ceregene Inc., FibroGen Inc., FzioMed Inc., FzioMed Inc.,
GeneMedix PLC, Insmed Inc., Johnson & Johnson, Janssen-Ortho, Inc., Lonza Group,
Maxygen, Inc., Merck Serono International S.A., NsGene A/S, PeproTech, Inc.,
Rentschler Biotechnologie GmbH, F. Hoffmann-La Roche Ltd., Chugai Pharmaceutical
Co. Ltd., Genentech, Inc., Shantha Biotechnics, Scil Proteins GmbH, and
Wockhardt Ltd. Market data and analytics are derived from primary and secondary
research. Company profiles are mostly extracted from URL research and reported
select online sources.

GROWTH FACTORS (BLOOD AND TISSUE) MCP-1217 A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability And Reporting Limitations I-1 Disclaimers I-2 Data
Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3
Product Definitions And Scope Of Study I-3 Blood Growth Factors I-3
Erythropoietins I-4 Colony Stimulating Factors I-4 Interferons I-4 Interleukins
I-4 Tissue Growth Factors I-4

II. EXECUTIVE SUMMARY

1. Introduction II-1 Growth Factors: A Preface II-1 Growth Factors: Their Role
and Related Applications II-1 Growth Factors: Adding a New Dimension II-1 Growth
Factors: Classification Based on Activity II-1 Recent Trends & Developments II-2
Recombinant Human Erythropoietin: Gradually Gaining Dominance II-2

2. Market Overview II-3 Analysis by Region II-3 US: The Single Largest Market
II-3 Growth Factors Market in Europe II-3 Market for Growth Factors in Rest of
World II-3

Table 1: World Market for Growth Factors (2000-2010): Geographic Regions Ranked
by CAGR -US, Europe, Japan, and Rest of World (includes corresponding
Graph/Chart) II-3 Analysis by Growth Factor Type II-4 EPO - The Lead `Factor`
II-4 Leading EPO Drugs Worldwide II-4 Market Comparison of Erythropoietin-Based
Drugs in America and European Union: Classification Based on Key Parameters II-5
Patent Expiries of Major Biopharmaceutical Drugs II-5

3. Market Dynamics II-6 Dethroning the Leaders II-6 Expiration of Patents Fuels
Competition and Sales II-6 India - At the Center Stage II-6 Side Effects - Still
a Concern II-6 CDER- A Regulatory Review Authority for Growth Factors II-7

4. Outlook II-8 Innovative Delivery System Shows Potential for Accelerating Use
of Growth Factors II-8 Cytokines- Vital Growth Propellers for the Future of New
Drugs II-8 Brain Derived Neurotrophic Factor (BDNF) Finds Increased Application
II-8 Age-Related Diseases - Their Influence on Effective Therapies II-8 Copaxone
Finds Novel Applications II-9 Mimetic Growth Factors - Exhibiting Promising
Potential II-9

5. Industry Issues II-10 Development of Cost Effective Methods - Need of the
Hour II-10 Influence of Neurotrophic Factors on Brain Cell Development II-10
Combination of Interferons and Ribavirin Develops More Anemia Cases II-10

6. Competitive Trends II-11 RegeneRx Focuses on Wound Healing Market II-11 DRL
Introduces a Program to Propel its Biogenerics Business II-11

7. Growth Factors - An Overview II-12 Blood Growth Factors II-12 Erythropoietins
II-12 Types of Erythropoietins II-12 Epoetin II-12 Darbepoetin II-13 Aranesp
II-13 Aranesp Vs Other EPOs II-13 Recombinant Human EPO (rHuEPO) II-13

Table 2: World Market for Erythropoietins (2000-2010): Geographic Regions Ranked
by CAGR - Europe, US, Japan and Rest of World (includes corresponding
Graph/Chart) II-14 Colony Stimulating Factors II-14 Granulocyte-Colony
Stimulating Factor II-14 Granulocyte Macrophage-Colony Stimulating Factor II-14
Other Colony Stimulating Factors II-14 Macrophage Colony Stimulating Factor
(M-CSF) II-15 Key Functions of M-CSF II-15 Side-Effects of Colony-Stimulating
Factors II-15

Table 3: World Market for Colony Stimulating Factors (2000-2010): Geographic
Regions Ranked by CAGR - Japan, Europe, US, and Rest of World (includes
corresponding Graph/Chart) II-15 Interferons II-15 Types of Interferons II-16
Interferon-gamma II-16 1a and 1b: Two Key Biochemical Forms of Interferon-ß
II-16 PEG-Intron II-16 Types of Interferons II-17

Table 4: World Market for Interferons as Blood Growth Factors (2000-2010):
Geographic Regions Ranked by CAGR - US, Europe, Japan, and Rest of World
(includes corresponding Graph/Chart) II-17 Interleukins II-17 Types of
Interleukins II-18

Table 5: World Market for Interleukins as Blood Growth Factors (2000-2010):
Geographic Regions Ranked by CAGR - Europe, Japan, US, and Rest of World
(includes corresponding Graph/Chart) II-19 Tissue Growth Factors II-19 Wound
Healing Growth Factors II-19 Neurotrophic Growth Factors II-19 Nerve Growth
Factor II-19 Vascular Endothelial Growth Factor (VEGF) II-20 Fibroblast Growth
Factor (FGF) II-20 Insulin-Like Growth Factor-I (IGF-I) II-20 Insulin-Like
Growth Factor-II (IGF-II) II-20 Tissue Growth Factors: Classification Based on
Key Source and Principal Activity II-20 Platelet - Derived Growth Factors in
Wound Healing II-21 Thrombopoietin (TPO) II-21

Table 6: World Market for Tissue Growth Factors (2000-2010): Geographic Regions
Ranked by CAGR - US, Europe, Japan, and Rest of World (includes corresponding
Graph/Chart) II-21 Growth Factors: Their Mode of Action in Tissue Repair II-21
Angiogenesis: Their Role in Wound Healing II-22 Angiogenesis As an Alternative
for Cardiac Stents II-22 Applications of Growth Factors II-22 Growth Factors:
Application by Compound and Supplier II-23 Growth Factors: Indicated
Applications by Site/Course of Action II-23

8. Research and Development Highlights II-24 Maxygen Updates on Factor VII
Program II-24 Evaluation of Extended Dosing Schedule of PROCRIT II-24 PROCRIT -
A Better Option II-24 Nerve Growth Factor Shows Promising Potential Against
Diabetes II-24 Cytokines and GM-CSF Found to be Closely Interlinked II-25 GM-CSF
Enhances Rate of Survival in Neonates II-25 rG-CSF Well Tolerated in Pneumonia
and Severe Sepsis Patients II-25 rG-CSF- Their Influence on Preterm Infants with
Sepsis II-26 Serum Macrophage Colony Stimulating Growth Factors Associated with
Thrombocyte and Monocyte II-26 Src Pathway Inactivation in Kit Impairs Blood
Cell Growth and Proliferation II-26 Cole Eye Institute Offers TIMP-3 Mechanism
for Preventing Abnormal Growth of Blood Vessels II-27 Effect of Brain Derived
Neurotrophic Factor on Retinal Cells II-27 Orcel Exhibits High Growth Factor for
Wound Healing and Cardiovascular Applications II-28 Drug Combination of
Macrophage Colony Stimulating Factor Shows Successful Tolerance Levels II-28
Neotrofin Triggers Neurotrophic Factors II-28 G-CSF Shows Capability for
Promoting Neutrophil Production II-28 Insulin-like Growth Factor-1 (IGF) Gene
Transfer Accelerates Wound Healing Process II-29 Hepatocyte Growth Factors -
Exhibiting Dual Role II-29 Cortex Pharmaceuticals Ampakines Promotes Expression
of Neurotrophin II-29 Granulocyte Colony Stimulating Factor Finds Application in
Treating Neonates II-30 Cerebrolysin Promotes Cognition II-30

9. Breakthroughs - A Review II-31 Novel Set of Human Cytokines Unveiled II-31
IGFBP-3 and its Potential to Ward Off Gastric Cancer II-31 Bone Morphogenic
Proteins Show Potential for Musculoskeletal Regeneration II-31 Growth Factors -
Their Role in Preventing Heart Stroke II-31 Growth Factor Proteins Shows
Promising Results for Treating Cancer II-31 Neurotrophic Growth Factor Primarily
Responsible for Loss of Vision II-32 Redox-Active Grape Seed Exhibits Favorable
Properties for Dermal Wound Healing II-32 Role of Brain-Derived Neurotrophic
Factor on Memory II-32 Nerve Growth Factor Found to Enhance Barium Current and
Insulin Secretion II-32 Lipid Peroxidation May be Associated with Wound Healing
II-32 Genentech Inc Unveils Molecule for Stimulating Growth of Blood Vessels
II-33 Connective Tissue Growth Factor Found to Promote Lung Fibroblast II-33
Influence of Insulin-Like Growth Factor on Growth II-33 Regeneron Discovers
Angiopoietins Targeted at Blood Vessel Growth and Repair II-34 Environment and
Insulin-Like Growth Factors Stimulate Risk of Cancer II-34 Cocktail of
Neurotrophic Factors Promotes Regeneration of Torn Nerves II-34 Growth Factors
Administration to Stimulate Tissue Repair II-34 Cytokine - Their Role in
Combating Hepatitis C Virus II-34 Axokine Yields Favorable Results Against
Obesity II-35 Cell Genesys Unveils GDNF Gene Therapy Targeted Against
Parkinson`s Disease II-35

10. Recent Industry Activity II-36 Pfizer Inks Exclusive Global Licensing
Agreement with Scil Technology II-36 ZGEN Initiates Ph II Trial of Interleukin
21 II-36 FzioMed Bags Health Canada Approval on Oxiplex II-36 NsGene A/S
Implants Encapsulated Cell in Patients II-36 Reliance Life Sciences Takes Over
Genemedix II-36 Fraunhofer Institute Introduces First Interferon Beta 1a to
Treat Multiple Sclerosis II-37 Shanghai Wanxing Inks Export Deal for Recombinant
Human Interferon II-37 Hemispherx Enters into Distribution Agreement with Armada
II-37 Bayer Launches US Pharmaceuticals Subsidiary II-38 Merck Inks Agreement
with Bristol-Myers Squibb and ImClone II-38 CoGenesys Signs Global Licensing
Agreement with Vegenics II-38 InterMune Inks New Supply Deal with Boehringer
Ingelheim II-38 Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals
II-39 Cambrex Divests Bioproducts and Biopharma Subsidiaries II-39 Dragon
Divests EPO Business II-39 Caregene and Genzyme Forms Partnership to Develop
Cere-120 II-39 Amgen Bags EC Approval on Use of Aranesp(R) in Paediatric
Patients II-40 NsGene to Undertake Phase Ib Clinical Trial of NsG0202 II-40
Roche Receives European approval for NeoRecormon II-40 Bolder Receives Two U.S.
Patents for Hematopoietic Factors II-40 Hospira Receives EC Approval on Retacrit
II-41 RLS to Initiate Clinical Trials of Erythropoietin II-41 InterMune Drops
Phase III trial of Interferon II-41 Chugai to Conduct Additional Trial on Epogin
II-41 Merck KGaA Acquires Serono Labs II-41 CytoPharm Acquires Low-Dose
Interferon License from Amarillo Biosciences II-42 Hospira Signs Agreements with
STADA and BIOCEUTICALS for Erythropoietin II-42 Biocon Bags GEAC Approval to
Conduct Clinical Trial of Granulocyte Colony Stimulating Factor II-42 SII to
Conduct Clinical Trials of Rdna Products II-42 Claris to Construct Production
Facility for EOP II-42 Mayne and Pliva to End Collaboration on Erythropoietin
Development II-43 GeneMedix Collaborates with CJ Corp. II-43 FzioMed and USC
Enter into Licensing Agreement for Oligopeptides II-43 Tercica Receives FDA
Approval For Increlex II-43 AnGes MG Enters Into An Agreement with Vical II-44
Corautus and BIA Sign Agreement for VEGF-2 plasmid DNA II-44 Dragon
Pharmaceuticals Acquires Oriental Wave II-44 Insmed Enters into Exclusive
Agreement with UCSF for IGF-1 Series II-44 Amrad and Ludwig Institute Jointly
Focus on the Development of VEGF-B II-44 GeneMedix Restructures Business II-45
pSivida Limited Collaborates with Ian Wark Research Institute II-45 Amgen
Acquires Tularik II-45 BMPI Signs up Luitpold Pharmaceuticals for FDA Approved
GEM 21S II-45 DPI Receives Approvals for Erythropoietin in Three New Markets
II-46 Chugai and Roche Expand Drug Research Synergies II-46 Dragon
Pharmaceuticals to Construct New Production Facility II-46 FibroGen Signs
Contract with Yamanouchi for Licensing EPO Small Molecule II-46 Insmed and
Tzamal Pharma Sign Agreement for Promoting SomatoKine II-46 Maxygen and
Rentschler Enter into a Contract for G-CSF II-46 Maxygen Signs Agreement with
Biovitrum for Manufacturing Beta Interferon II-46 Dragon Pharmaceuticals Signs
Agreement with Zhongkai II-47 Dragon Pharmaceuticals Enters into Definitive
Agreement with Oriental Wave II-47 Zymogenetics Bags US FDA Clearance II-47
Ceregene Bags Patent II-47

11. Strategic Corporate Developments in Recent Past II-48 AME Enters into Third
Collaboration with Eli Lilly and Company II-48 ViaCell Enters into Licensing
Agreement and Collaboration with Amgen II-48 Ceregene Enters into Licensing
Agreement with Genentech II-48 BIOPHARM GmbH Enters into Licensing Contract with
DePuy II-48 Maxygen Enters into a Deal with Roche Holding II-48 Dragon
Pharmaceuticals Bags Market Approval from Chinese SDA II-49 GeneMedix Signs
Agreement with SkyePharma II-49 Neurotech Enters into Licensing Agreement with
Amgen II-49 Ceregene Enters into a Licensing Agreement with Washington
University II-49 NeoTherapeutics Receives US Patent for Stimulating
Neuritogenesis II-49 BioSET Bags Global Exclusive License for Novel Growth
Factor Technology II-49 ViaCell Acquires Cerebrotec II-50 Fibrogen Collaborates
with Sankyo II-50 Prescient NeuroPharma Collaborates with SRIB II-50 Dragon
Pharmaceuticals Signs Agreement with Renapharm AB and Transworld II-50 Baxter
Bags Exclusive Worldwide Rights for Epoetin Omega II-50 Ortec International Bags
FDA PMA for OrCel II-50 GeneMedix Bags Chinese SDA Approval II-51 NsGene
Collaborates with ARIAD Pharmaceuticals II-51 Regeneron Enters into Agreement
with Emisphere Technologies II-51 NsGene A/S Signs Agreement with Biogen Inc
II-51 NTB Enters into BioInformatics Outsourcing Agreement with HSC II-52

12. Product Launches in Recent Past II-53 Wockhardt Introduces Wepox Recombinant
Erythropoietin Drug II-53 Shanta Biotechnics Unveils Shanferon II-53 SkinMedica
Unveils TNS Recovery Complex Gel II-53 CellGenix Unveils Cytokines for Cell
Applications II-53 Cel-Sci Corporation Develops Multikine II-53 Wockhardt
Limited Unveils EPOX II-53

13. Focus on Select Global Players II-54 Amgen, Inc. (USA) II-54 BioMimetic
Therapeutics, Inc. (USA) II-54 Biopharm GmbH (Germany) II-54 Bolder
Biotechnology, Inc. (USA) II-54 Alseres Pharmaceuticals, Inc. (USA) II-55
Ceregene Inc. (USA) II-55 FibroGen Inc. (USA) II-55 FzioMed Inc. (USA) II-55
GeneMedix Plc. (UK) II-56 Insmed Inc. (USA) II-56 Johnson & Johnson (USA) II-56
Janssen-Ortho Inc. (Canada) II-57 Lonza Group (Switzerland) II-57 Maxygen, Inc.
(USA) II-57 Merck Serono International S.A. (Switzerland) II-57 NsGene A/S
(Denmark) II-58 PeproTech Inc. (USA) II-58 Rentschler Biotechnologie GmbH
(Germany) II-58 F. Hoffmann-La Roche Ltd (Switzerland) II-58 Chugai
Pharmaceutical Co. Ltd. (Japan) II-59 Genentech Inc. (USA) II-59 Shantha
Biotechnics (India) II-59 Scil Proteins GmbH (Germany) II-60 Wockhardt Ltd.
(India) II-60

14. Global Market Perspective II-61

Table 7: World Recent Past, Current & Future Analysis for Growth Factors (Blood
and Tissue) by Geographic Region - US, Japan, Europe, and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-61

Table 8: World Long-term Projections for Growth Factors (Blood and Tissue) by
Geographic Region - US, Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-62

Table 9: World 10-Year Perspective for Growth Factors (Blood and Tissue) by
Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe,
and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding
Graph/Chart) II-63

Table 10: World Recent Past, Current & Future Analysis for Blood Growth Factors
by Geographic Region - US, Japan, Europe, and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-64

Table 11: World Recent Past, Current & Future Analysis for Blood Growth Factors
by Type - Erythropoietins, Colony Stimulating Factors, Interferons and
Interleukins Markets Independently Analyzed with Annual Sales in US$ Million for
Years 2000 through 2010 (includes corresponding Graph/Chart) II-65

Table 12: World Long-term Projections for Blood Growth Factors by Geographic
Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-66

Table 13: World Long-term Projections for Blood Growth Factors by Type -
Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins
Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) II-67

Table 14: World 10-Year Perspective for Blood Growth Factors by Geographic
Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of
World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-68

Table 15: World 10-Year Perspective for Blood Growth Factors by Type -
Percentage Breakdown of Value Sales for Erythropoietins, Colony Stimulating
Factors, Interferons and Interleukins Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) II-69

Table 16: World Recent Past, Current & Future Analysis for Erythropoietins by
Geographic Region - US, Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-70

Table 17: World Long-term Projections for Erythropoietins by Geographic Region -
US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-71

Table 18: World 10-Year Perspective for Erythropoietins by Geographic Region -
Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World
Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-72

Table 19: World Recent Past, Current & Future Analysis for Colony Stimulating
Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-73

Table 20: World Long-term Projections for Colony Stimulating Factors by
Geographic Region - US, Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-74

Table 21: World 10-Year Perspective for Colony Stimulating Factors by Geographic
Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of
World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-75

Table 22: World Recent Past, Current & Future Analysis for Interferons as Blood
Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) II-76

Table 23: World Long-term Projections for Interferons as Blood Growth Factors by
Geographic Region - US, Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-77

Table 24: World 10-Year Perspective for Interferons as Blood Growth Factors by
Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe,
and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding
Graph/Chart) II-78

Table 25: World Recent Past, Current & Future Analysis for Interleukins as Blood
Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) II-79

Table 26: World Long-term Projections for Interleukins as Blood Growth Factors
by Geographic Region - US, Japan, Europe, and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for Years 2011 through
2015 (includes corresponding Graph/Chart) II-80

Table 27: World 10-Year Perspective for Interleukins as Blood Growth Factors by
Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe,
and Rest of World Markets for 2003, 2008 & 2012 (includes corresponding
Graph/Chart) II-81

Table 28: World Recent Past, Current & Future Analysis for Tissue Growth Factors
by Geographic Region - US, Japan, Europe, and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-82

Table 29: World Long-term Projections for Tissue Growth Factors by Geographic
Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-83

Table 30: World 10-Year Perspective for Tissue Growth Factors by Geographic
Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of
World Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-84

III. MARKET

1. The United States III-1 A.Market Analysis III-1 Current and Future Analysis
III-1 EPO Market Scenario III-1 Key Market Driver for EPO III-1 Leading EPO
Drugs in the US III-1 Recent Industry Activity III-2 Strategic Corporate
Developments in Recent Past III-6 Product Launches in Recent Past III-8 Key
Players III-9 B.Market Analytics III-12

Table 31: US Recent Past, Current & Future Analysis for Growth Factors by Type -
Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding
Graph/Chart) III-12

Table 32: US Long-term Projections for Growth Factors by Type - Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors, Interferons and
Interleukins) and Tissue Growth Factors Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-13

Table 33: US 10-Year Perspective for Growth Factors by Type - Percentage
Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors
Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) III-14

2. Japan III-15 A.Market Analysis III-15 Current and Future Analysis III-15
Erythropoietin Market: Competitive Scenario III-15 Leading EPO Drugs in Japan
III-15 Market Scenario for Biotech Products III-15 Biotech Market Backed by
Public Assistance III-15 Recent Industry Activity III-16 Chugai Pharmaceutical
Co. Ltd. - A Key Player III-16 B.Market Analytics III-17

Table 34: Japanese Recent Past, Current & Future Analysis for Growth Factors by
Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-17

Table 35: Japanese Long-term Projections for Growth Factors by Type - Blood
Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and
Interleukins) and Tissue Growth Factors Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-18

Table 36: Japanese 10-Year Perspective for Growth Factors by Type - Percentage
Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors
Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) III-19

3. Europe III-20 A.Market Analysis III-20 Current and Future Analysis III-20
Erythropoietin Market Scenario in the Recent Past III-20 Leading EPO Drugs in
Europe III-20 Recent Industry Activity III-20 Strategic Developments in Recent
Past III-22 Product Launch in Recent Past III-24 Key Players III-24 B.Market
Analytics III-27

Table 37: European Recent Past, Current & Future Analysis for Growth Factors by
Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-27

Table 38: European Long-term Projections for Growth Factors by Type - Blood
Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and
Interleukins) and Tissue Growth Factors Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-28

Table 39: European 10-Year Perspective for Growth Factors by Type - Percentage
Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors
Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart) III-29

4. Rest of World III-30 A.Market Analysis III-30 Current and Future Analysis
III-30 An Overview of Indian Market III-30 Erythropoiet III-30 G-CSF III-30
Interferon III-31 Recent Industry Activity III-31 Strategic Developments in
Recent Past III-33 Product Launches in Recent Past III-34 Key Players III-35
B.Market Analytics III-36

Table 40: Rest of World Recent Past, Current & Future Analysis for Growth
Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating
Factors, Interferons and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) III-36

Table 41: Rest of World Long-term Projections for Growth Factors by Type - Blood
Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and
Interleukins) and Tissue Growth Factors Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-37

Table 42: Rest of World 10-Year Perspective for Growth Factors by Type -
Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins,
Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth
Factors Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)
III-38

IV. COMPETITIVE LANDSCAPE

-Alseres Pharmaceuticals, Inc. (USA) -Amgen, Inc. (USA) -BioMimetic
Therapeutics, Inc. (USA) -Biopharm GmbH (Germany) -Bolder Biotechnology, Inc.
(USA) -Ceregene Inc. (USA) -Chugai Pharmaceutical Co. Ltd. (Japan) -F.
Hoffmann-La Roche Ltd (Switzerland) -FibroGen Inc. (USA) -FzioMed Inc. (USA)
-GeneMedix Plc. (UK) -Genentech Inc. (USA) -Insmed Inc. (USA) -Janssen-Ortho
Inc. (Canada) -Johnson & Johnson (USA) -Lonza Group (Switzerland) -Maxygen, Inc.
(USA) -Merck Serono International S.A. (Switzerland) -NsGene A/S (Denmark)
-PeproTech Inc. (USA) -Rentschler Biotechnologie GmbH (Germany) -Scil Proteins
GmbH (Germany) -Shantha Biotechnics (India) -Wockhardt Ltd. (India)

To order this report:World Growth Factors (Blood And Tissue) Market

http://www.reportlinker.com/p098265/World-Growth-Factors-(Blood-And-Tissue)-Market.html

More market research reports here!

Reportlinker
Nicolas: nbo@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

Copyright Business Wire 2009